

Price: 1,492

Recommendation: Buy

Industry: Pharmaceuticals

Sector: Healthcare

Report Date: 03-Apr-2025

Cipla's recent earnings call highlighted strategic initiatives for growth, reporting record quarterly revenue and EBITDA margins. The company focuses on execution excellence and strategic investments, expanding its field force in India and maintaining margins in South Africa. Cipla is diversifying with innovations like CipAir, an AI app for asthma, and exploring acquisitions to fill portfolio gaps. Challenges include regulatory clearances and supply disruptions, but Cipla's proactive approach and strong cash position support sustained growth.

Sales		Profit & Loss		Profitability Matrix	
Current Year	18284 Cr	Operating Profit(Year)	5288 Cr	Operating Profit Margin	28.9 %
Previous Year	14345 Cr	Operating Profit(Quarter)	1662 Cr	EBITDA Margin	30.08 %
Current Quarter	4971 Cr	PAT (Year)	4034 Cr	Net Profit Margin	24.3 %
Previous Quarter	4775 Cr	PAT (Quarter)	1438 Cr	EPS	58.3
Revenue (QYoY)	4381 Cr				
Valuation Matrix		Growth(YoY)		Growth(QoQ)	
Trailing P/E	25.9	Sales Growth	10.8 %	Sales Growth	4.1 %
PEG Ratio	1.49	PAT Growth	57.89 %	Sales Growth QYoY	13.47 %
EV/EBITDA	18.4	EPS Growth	15.45 %	PAT Growth	22.07 %
P/B	4.17	Dividend Yield	0.87	PAT Growth QYoY	41.26 %
Capital Allocation		Holdings		Leverage	
RoE	15.3 %	Promoter	29.2 %	Debt/Equity	0.00
RoA	13.8 %	FII	26.6 %	Debt	43.0 Cr
RoCE	18.6 %	DII	27.5 %	Market Cap	120456 Cr
RoIC	33.2 %	Public	16.4 %	Enterprise value	120109 Cr
		No of Shares	80.8 Cr	Cash Equivalents	390 Cr

source : Company filings

Company's Overview Based on Recent Concall and Performance:


Cipla's recent earnings call highlighted several strategic initiatives and business strategies aimed at sustaining growth and enhancing market presence. The company reported its highest-ever quarterly revenue and all-time high EBITDA margins, driven by strong performances across its core markets, including India, North America, South Africa, and EMEU. Cipla's focus on execution excellence and strategic investments in its pipeline have been pivotal in achieving these results. The company has introduced a retail task force in India and expanded its field force, particularly in chronic therapies, to enhance business visibility. Additionally, Cipla has been selective in tender businesses in South Africa to maintain margins, contributing to robust growth in the region.

Cipla is actively pursuing diversification and innovation to strengthen its business model. The company has launched CipAir, an AI-powered mobile application for asthma screening in India, and continues to invest in its consumer health business, which has shown strong traction with anchor brands like Nicotex, Omnigel, and Cipladine maintaining leadership positions. Cipla's diversification strategy is further supported by its well-diversified business portfolio, with EMEU and One Africa businesses accounting for over 25% of total revenue. The company is also exploring acquisition opportunities to address portfolio gaps and drive growth, particularly in differentiated assets in the US and other attractive markets.

Looking ahead, Cipla is focused on resolving supply issues in North America, maximizing commercial execution, and expediting product launches from its US facility. The company plans to launch key assets like generic Advair and Abiraxane, which are expected to significantly contribute to the US top line. In India, Cipla aims to continue its growth momentum in branded prescriptions and trade generics, while in EMEU, the focus is on maximizing the top line and identifying growth markets. The company's strategic initiatives and robust pipeline position it well for future growth and scaling.

While Cipla's performance has been commendable, there are areas for improvement. The company faces challenges with regulatory clearances and supply disruptions, which have delayed some product launches. Additionally, maintaining the high EBITDA margins achieved in the recent quarter may be challenging due to seasonal factors and market dynamics. However, Cipla's proactive approach to addressing these challenges, coupled with its strong cash position and strategic focus on innovation and diversification, provides a solid foundation for sustained growth. The company's commitment to enhancing operational efficiencies and expanding its market presence bodes well for its future prospects.

CIPLA Daily Closing One Year Price Chart



Name	Mar Cap (Rs. Cr.)	P/E	ROE	Sales(G) QoQ	Sales(G) QYoY	PAT(G) QoQ	PAT(G) QYoY
Mankind Pharma	99777.98	51.63	19.71%	-5.26%	8.48%	-30.88%	-10.01%
Dr Reddy's Labs	96175.14	17.86	21.39%	4.27%	15.81%	11.83%	1.69%
Lupin	95682.33	33.32	14.14%	1.67%	10.97%	0.30%	39.48%
Zydus Lifesci.	90606.38	20.01	20.67%	0.61%	16.96%	12.39%	33.34%
Aurobindo Pharma	68926.90	19.46	11.53%	2.34%	8.53%	3.50%	-9.69%

Aspect	Commentary
Revenue	The company achieved a significant increase in revenue, with a year-over-year growth of 10.8% and a quarter-over-quarter growth of 4.1%. This indicates a strong upward trend in sales performance, reflecting effective market strategies and product demand.
Profit & Loss	Operating profit and PAT showed robust growth, with PAT increasing by 57.89% YoY. This highlights efficient cost management and revenue generation, contributing to a healthy bottom line.
Profitability Matrix	The company maintains strong profitability with an operating profit margin of 28.9% and a net profit margin of 24.3%. These figures suggest effective cost control and pricing strategies, ensuring sustainable profit levels.
Valuation Matrix	The valuation metrics, including a trailing P/E of 25.9 and a PEG ratio of 1.49, indicate a balanced valuation relative to growth prospects. The EV/EBITDA of 18.4 suggests a fair market valuation.
Growth (YoY)	Year-over-year growth metrics are impressive, with sales and PAT growth at 10.8% and 57.89%, respectively. This reflects strong operational performance and market expansion efforts.
Growth (QoQ)	Quarter-over-quarter growth shows positive momentum, with sales and PAT growth at 4.1% and 22.07%, respectively. This indicates effective short-term strategies and market responsiveness.
Capital Allocation	The company demonstrates efficient capital allocation with a RoE of 15.3% and RoCE of 18.6%. These metrics reflect strong returns on equity and capital employed, supporting shareholder value.
Holdings	The shareholding pattern is diversified, with promoters holding 29.2% and significant institutional investments. This indicates confidence in the company's governance and growth potential.
Leverage	The company maintains a strong financial position with a debt/equity ratio of 0.00, indicating no reliance on debt financing. This enhances financial stability and flexibility for future investments.

Analyst viewpoint: Cipla demonstrates significant promise as a short to mid-term investment, fueled by strong operational growth and robust financial metrics. The company has reported a quarter-over-quarter sales growth of 4.1% and profit after tax (PAT) growth of 22.07%, highlighting effective market strategies and product demand. Its valuation metrics, such as a trailing P/E of 25.9 and a PEG ratio of 1.49, suggest a balanced valuation aligned with growth prospects. Cipla's strategic initiatives, including the diversification into AI-driven solutions and targeted acquisitions, underline its commitment to sustaining market leadership. The company's capital allocation is efficient, evidenced by a strong return on equity (RoE) of 15.3% and a debt/equity ratio of 0.00, indicating a sustainable growth path without over-leverage.

In the competitive landscape, Cipla's proactive expansion into chronic therapies and strategic focus on execution excellence in India and other regions further solidify its market presence. The company continues to innovate with products like CipAir and seeks to optimize supply chain operations, demonstrating resilience against regulatory and market challenges. However, it is noteworthy that sustaining high EBITDA margins could be challenging due to market dynamics and seasonal factors. Despite these headwinds, Cipla's robust cash position and strategic investments position it well for continued growth, making it a compelling choice for investors looking for a promising pharmaceutical leader.

Please read detailed disclosure on next page.

Explanation of Investment Rating*	
Investment Rating	Expected Return (over 12-month)
BUY	>=15%
SELL	<-10%
NEUTRAL	>-10% to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (hereinafter referred to as the Regulations).

1. GOALZEN CAPITAL SERVICES PRIVATE LIMITED is a SEBI-Registered Research Analyst having SEBI registration number INH000013448. GOALZEN CAPITAL SERVICES PRIVATE LTD ("GoalFi" or "We"), the research entity, is engaged in providing research services on securities and information on personal financial products. This Research Report (called Report) is prepared and distributed by GOALZEN CAPITAL SERVICES PRIVATE LIMITED with brand name 'GoalFi' (brand name trademarked to research analyst and company director 'Robin Arya') and used by GOALZEN CAPITAL SERVICES PRIVATE LIMITED with mutual consent.

2. GOALZEN CAPITAL SERVICES PRIVATE LIMITED, its partners, employees, directors or agents, do not have any material adverse disciplinary history as on the date of publication of this report.

3. I, Robin Arya, author/s and the name/s in this report, hereby certify that all of the views expressed in this research report accurately reflect my/our views about the subject issuer(s) or securities. I/We also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. I/we or my/our relative or GOALZEN CAPITAL SERVICES PRIVATE LIMITED do not have any financial interest in the subject company.

4. I/we or my/our relative or GOALZEN CAPITAL SERVICES PRIVATE LIMITED do not have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. I/we or my/our relative or GOALZEN CAPITAL SERVICES PRIVATE LIMITED do not have any material conflict of interest. I/we have not served as director / officer, etc. in the subject company in the last 12-month period.

5. I, Robin Arya, do not hold this stock as part of my investment portfolio at the date of recommendation. I/analysts in the Company have not traded in the subject stock thirty days preceding this research report and will not trade within five days of publication of the research report as required by regulations.

6. GOALZEN CAPITAL SERVICES PRIVATE LIMITED has not received any compensation from the subject company in the past twelve months. GOALZEN CAPITAL SERVICES PRIVATE LIMITED has not been engaged in market making activity for the subject company.

7. In the last 12-month period ending on the last day of the month immediately preceding the date of publication of this research report, GOALZEN CAPITAL SERVICES PRIVATE LIMITED has not received compensation or other benefits from the subject company of this research report or any other third-party in connection with this report.

Analyst Certification:

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclaimers:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent.

This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment.

The investment discussed or views expressed may not be suitable for all investors. Certain transactions - including those involving futures, options, another derivative product as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document.

This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of GOALZEN CAPITAL SERVICES PRIVATE LIMITED. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject GOALZEN CAPITAL SERVICES PRIVATE LIMITED to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt GOALZEN CAPITAL SERVICES PRIVATE LIMITED or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold GOALZEN CAPITAL SERVICES PRIVATE LIMITED or any of its affiliates or employees responsible for any such misuse and further agrees to hold GOALZEN CAPITAL SERVICES PRIVATE LIMITED or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of GOALZEN CAPITAL SERVICES PRIVATE LIMITED only.

GOALZEN CAPITAL SERVICES PRIVATE LIMITED has a contractual arrangement with a vendor - Smallcase Technologies Private Limited (STPL) whereby STPL provides technology solutions and related back-end infrastructure along with support for back-office related operations & processes. STPL does not provide any investment advice or recommendation nor does it make any claim of returns or performance with respect to any advice or recommendation.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Terms & Conditions:

These Terms and Conditions govern the use of the research subscription services provided by GOALZEN CAPITAL SERVICES PRIVATE LTD ("GoalFi" or "We"). By subscribing to our services, you agree to these terms, if you disagree with any part of the terms, you must not use our services.

Payment and Renewal:

The subscription fee is non-refundable. No such requests over email or any other channel requesting for refund or for pro-rata refund will be acknowledged if smallcase constituents or research provided is accessed by the user. Please do not subscribe if you disagree with any part of the terms. Subscription renewals will be charged the standard rate unless otherwise notified.

Limitation of Liability:

GoalFi provides research based on data and analysis. The subscriber acknowledges that all investment decisions carry inherent risks, and GoalFi shall not be liable for any losses incurred based on our research.

No Investment Advice:

The content provided under the subscription is purely for informational purposes and should not be construed as investment advice. GoalFi, being a SEBI Registered Research Analyst (RA), provides research insights and not investment advisory services.

Termination:

GoalFi reserves the right to terminate the subscription at any time due to non-compliance with these terms or any other reasons deemed appropriate by us and no refund will be made.

No Guarantee: While we strive to provide accurate and reliable research, there is no guarantee on the returns or performance of the recommendations. Investing in securities involves risks, and there's the potential for losing money.

Review and Update: Our research products are reviewed and updated periodically to reflect the latest market conditions and insights. However, market conditions can change rapidly, and there's no guarantee that the conditions on which recommendations and insights are based will remain the same.

Research Analyst Details:

Name: Robin Arya

Email: smallcase@goalfi.in

Contact: +91-9394306085

GOALZEN CAPITAL SERVICES PRIVATE LIMITED

CIN: U66190TS2023PTC176030

Address: Co ikeva Office 10, Level 3, NSL Centrum, Serene Estate Pvt Ltd, Site No. Phase I and II, Opp KPHB Colony Lane Opp. Forum Mall Kukatpally, HYDERABAD, TELANGANA, 500072

Support Telephone: +91 9063309052, Support Email – support@goalfi.in

Customer having any query/feedback/ clarification/ In case of grievances for any of the services rendered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED, write to hello@goalfi.app

Website: goalfiresearch.smallcase.com